Today marks World Bronchiectasis Day, and the American Lung Association has introduced a new campaign to aid individuals living with bronchiectasis. This chronic lung condition affects between 350,000 and 500,000 adults in the United States. The campaign's goal is to educate those affected on disease management, connect them with emotional support, and ultimately enhance their quality of life.
Bronchiectasis involves the widening and scarring of airways due to repeated inflammation and infection. This results in difficulty clearing mucus from the lungs, leading to persistent coughs, shortness of breath, frequent infections, and reduced lung function.
“While there is currently no cure for bronchiectasis, early diagnosis, effective management and a solid support system can help people with the disease lead healthy and active lives,” stated Harold Wimmer, President and CEO of the American Lung Association. “Through education, support and empowering individuals to communicate effectively with their healthcare providers, we can help patients better manage their symptoms and prevent serious complications.”
The awareness campaign by the American Lung Association is offered at no cost. It highlights that bronchiectasis is more prevalent among women and older adults. In 40% of cases, its underlying cause remains unknown. Treatment typically includes airway clearance techniques, inhaled medications, antibiotics for managing infections, and sometimes oxygen therapy. Although it shares some symptoms with COPD (Chronic Obstructive Pulmonary Disease), bronchiectasis requires distinct treatment strategies.
For more information on bronchiectasis or to access educational resources, visit Lung.org/bronchiectasis.
Boehringer Ingelheim supports this awareness initiative.
